Patents by Inventor Matthew V. Lorenzi
Matthew V. Lorenzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230030983Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.Type: ApplicationFiled: March 18, 2022Publication date: February 2, 2023Applicant: ASTEX THERAPEUTICS LTDInventors: Jayaprakash KARKERA, Suso Jesus PLATERO, Raluca VERONA, Matthew V. LORENZI
-
Publication number: 20200108141Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.Type: ApplicationFiled: October 23, 2019Publication date: April 9, 2020Applicant: ASTEX THERAPEUTICS LTDInventors: Jayaprakash KARKERA, Suso Jesus PLATERO, Raluca VERONA, Matthew V. LORENZI
-
Patent number: 10478494Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.Type: GrantFiled: March 24, 2016Date of Patent: November 19, 2019Assignee: ASTEX THERAPEUTICS LTDInventors: Jayaprakash Karkera, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
-
Publication number: 20160287699Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.Type: ApplicationFiled: March 24, 2016Publication date: October 6, 2016Inventors: Jayaprakash KARKERA, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
-
Patent number: 7521044Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.Type: GrantFiled: August 1, 2006Date of Patent: April 21, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Donald G. Jackson, Matthew V. Lorenzi, Liana M. Lee, John N. Feder
-
Patent number: 7297493Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.Type: GrantFiled: November 18, 2004Date of Patent: November 20, 2007Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Matthew V. Lorenzi, Toru Miki
-
Patent number: 7199227Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.Type: GrantFiled: June 14, 2002Date of Patent: April 3, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Donald G. Jackson, Matthew V. Lorenzi, Ricardo M. Attar, Marco Gottardis, Liana M. Lee, John N. Feder
-
Patent number: 7138246Abstract: Methods for determining whether a test agent inhibits a 17?-HSD3, the methods comprising: obtaining a recombinant host cell that expresses the 17?-HSD3; obtaining a reaction mixture comprising the 17?-HSD3, androstenedione, and the test agent; measuring the amount of testosterone in the reaction mixture by a scintillation proximity assay (SPA) using SPA beads conjugated with a testosterone-specific antibody, wherein when the amount of testosterone is lower in the presence of a test agent than in the absence of the test agent, the test agent is identified as an inhibitor of the 17?-HSD3.Type: GrantFiled: February 28, 2005Date of Patent: November 21, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Matthew V. Lorenzi, Thomas Spires, Dan You, Roberto Weinmann, Marco Gottardis
-
Patent number: 6831170Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.Type: GrantFiled: June 12, 2003Date of Patent: December 14, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Matthew V. Lorenzi, Toru Miki
-
Publication number: 20040122080Abstract: Chemotherapeutic combinations of selected cytotoxic agents and RAR&agr;/&bgr; selective agonists or RAR pan antagonists for use in treating cancer and lowering the effective cytotoxic dose of the selected cytotoxic agent are provided.Type: ApplicationFiled: February 19, 2004Publication date: June 24, 2004Inventors: Valerie S Vivat-Hannah, Matthew V Lorenzi, Marco M Gottardis, Fred Christopher Zusi
-
Publication number: 20030224454Abstract: Human solute carrier family 7, member 11 (hSLC7A11) polynucleotides and polypeptides. Also provided are expression vectors, recombinant host cells and processes for producing recombinant host cells, processes for producing said polypeptides, and methods for identifying receptors that are capable of binding to a solute carrier family 7, member 11 molecule.Type: ApplicationFiled: May 29, 2003Publication date: December 4, 2003Inventors: Rolf Peter Ryseck, Matthew V. Lorenzi, David K. Bol
-
Publication number: 20030212260Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.Type: ApplicationFiled: June 12, 2003Publication date: November 13, 2003Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Matthew V. Lorenzi, Toru Miki
-
Publication number: 20030161830Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.Type: ApplicationFiled: June 14, 2002Publication date: August 28, 2003Inventors: Donald G. Jackson, Matthew V. Lorenzi, Ricardo M. Attar, Marco Gottardis
-
Patent number: 6608181Abstract: A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.Type: GrantFiled: August 29, 2001Date of Patent: August 19, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Matthew V. Lorenzi, Toru Miki
-
Publication number: 20020032310Abstract: A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.Type: ApplicationFiled: August 29, 2001Publication date: March 14, 2002Applicant: The Govt. of the U.S.A., The Secretary of the Department of Health and Human ServicesInventors: Matthew V. Lorenzi, Toru Miki
-
Patent number: 6323316Abstract: A novel gene designated as FRAG 1 and its encoded protein are disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies.Type: GrantFiled: December 15, 1998Date of Patent: November 27, 2001Assignee: The United States of America as represented by the Secretary of the Department of and Human ServicesInventors: Matthew V. Lorenzi, Toru Miki